Vanda Pharmaceuticals has reported that results from a Phase II study demonstrated that its investigational agent VEC-162 improved key sleep measures in adults with transient insomnia.

The primary objectives of the study were to evaluate the efficacy of VEC-162 in shifting patients' circadian rhythm and in improving time to persistent sleep when compared with placebo.